Sudarshan Pharma Industries Complete Financial Statements
In FY2026, Sudarshan Pharma Industries (SUDARSHAN) reported revenue ₹225 Cr, net profit ₹11 Cr and EPS ₹0.48, with a net profit margin of 4.9% and ROE of 7.1%. Full financial statements from FY2020 to FY2026 (7 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Sudarshan Pharma Industries share price screener.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
SUDARSHAN Revenue, Net Profit & EBITDA — Year-on-Year Growth
SUDARSHAN YoY (Mar 2025 vs Mar 2026) — revenue +38.9%, net profit +57.1%, EBITDA +60.0%, expenses +36.7%. Examine SUDARSHAN quarterly results for recent quarterly revenue, profit and EPS trends.
SUDARSHAN Income Statement — Revenue, EBITDA & Net Profit
Sudarshan Pharma Industries revenue ₹225 Cr, EBITDA ₹24 Cr, net profit ₹11 Cr, EPS ₹0.48 (2026) — net profit margin 4.9%. Analyse Sudarshan Pharma Industries shareholding analysis to track promoter, FII and institutional holdings.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 225 | 171 | 162 | 147 | 170 | 129 | 232 | 100 | 116 |
| Expenses | 201 | 160 | 147 | 134 | 157 | 117 | 217 | 97 | 108 |
| EBITDA | 24 | 11 | 15 | 12 | 12 | 12 | 15 | 3 | 9 |
| Operating Profit Margin % | 9.00% | 5.00% | 9.00% | 8.00% | 6.00% | 9.00% | 6.00% | 2.00% | 7.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 8 | 6 | 4 | 6 | 6 | 4 | 6 | 4 | 4 |
| Profit Before Tax | 16 | 4 | 10 | 5 | 5 | 8 | 9 | -2 | 4 |
| Tax | 4 | 0 | 3 | 1 | 1 | 2 | 2 | 0 | 1 |
| Net Profit | 11 | 4 | 7 | 4 | 4 | 6 | 7 | -1 | 3 |
| Earnings Per Share (₹) | 0.48 | 0.16 | 0.29 | 0.16 | 0.18 | 0.24 | 0.27 | -0.05 | 0.12 |
SUDARSHAN Balance Sheet — Assets, Liabilities & Shareholders' Equity
SUDARSHAN total assets ₹642 Cr, total equity ₹155 Cr, total liabilities ₹ Cr (2026) — ROE 7.1%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Total Assets | 642 | 402 | 283 | 233 | 138 | 99 | 58 |
| Current Assets | 490 | 335 | 242 | 199 | 130 | 88 | 47 |
| Fixed Assets | 102 | 24 | 26 | 20 | 7 | 6 | 6 |
| Capital Work in Progress | 3 | 6 | 2 | 0 | 1 | 0 | 0 |
| Investments | 219 | 2 | 2 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 371 | 254 | 213 | 131 | 93 | 53 |
| LIABILITIES | |||||||
| Total Liabilities | |||||||
| Current Liabilities | 29 | 11 | 11 | 13 | 5 | 6 | 7 |
| Non-Current Liabilities | |||||||
| SHAREHOLDERS' EQUITY | |||||||
| Total Equity | 155 | 132 | 112 | 101 | 30 | 23 | 20 |
| Share Capital | 24 | 24 | 24 | 24 | 10 | 10 | 10 |
| Reserves & Surplus | 131 | 104 | 88 | 77 | 20 | 13 | 10 |
SUDARSHAN Cash Flow Statement — Operating, Investing & Financing
Sudarshan Pharma Industries operating cash flow ₹35 Cr, investing ₹-20 Cr, financing ₹-14 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 |
|---|---|---|---|---|---|---|
| Operating Activities | 35 | 6 | -29 | -4 | 3 | 1 |
| Investing Activities | -20 | -6 | -26 | -2 | -1 | -3 |
| Financing Activities | -14 | -12 | 66 | 4 | -2 | 0 |
| Net Cash Flow | 0 | -12 | 12 | -1 | 0 | -2 |